$2 / month

Comment and reply across TML.

Start or manage membership

Most pulsed

Advertisement Sinscents Bad Intentions. Great Candles.

Latest from other desks

tml.the modern leap
Money / Business

Novartis Signs OBI ADC Deal Worth Over $2 Billion

Novartis has signed a collaboration and license agreement with Taiwan's OBI Pharma for its antibody-drug conjugate platform, OBI announced on Monday, November 16. Novartis pays $30 million upfront and OBI becomes eligible for development, regulatory and commercial milestones that put the deal's total potential value above $2 billion.

Novartis headquarters in Basel, Switzerland, the buyer in the ADC platform deal (archive). Photo: Andrew Hecht, CC BY 2.0, via Wikimedia Commons.
Summary

The $30 million is the only money that exists today. The other $2 billion is a ladder of milestones that pays out only if drugs built on OBI's conjugation chemistry survive development, and that's the structure to read, not the headline number.

Tap a passage. React to the part that matters.

OBI Pharma has entered a collaboration and license agreement with Novartis Pharma AG to develop next-generation antibody-drug conjugates with novel payloads, the Taipei company announced on Monday, November 16. Novartis receives worldwide rights, on an exclusive basis, to OBI's ADC platform patents and know-how for selected Novartis payload classes that the companies aren't disclosing.

The money splits into a certainty and a possibility, and they aren't close in size. OBI receives an upfront payment of $30 million. Everything above that is milestone money tied to development, regulatory and commercial events, with a total potential deal value exceeding $2 billion if the ladder is climbed. Milestone totals in platform deals are ceilings, not forecasts, and most rungs on most ladders are never reached.

What Novartis is buying is conjugation chemistry. An antibody-drug conjugate is an antibody that carries a toxic payload directly to a cancer cell, so the drug concentrates where the tumor is instead of circulating everywhere. OBI's Obrion platform is the tooling for attaching that payload, built around GlycOBI, a glycan-based conjugation technology the company describes as plug-and-play across antibodies, linkers and payloads, alongside its EndoSymeOBI, HYPrOBI and GlycOBI DUO technologies.

The release gives the platform's mechanics in outline. Obrion integrates the ADC-enabling technologies into one system, and GlycOBI sits at its core: a glycan-based conjugation method, meaning the payload is attached at sugar sites on the antibody rather than at random points, which produces a more uniform drug. Uniformity is the manufacturing argument for the whole platform class, because a conjugate that comes out the same way every batch is easier to dose, test and scale.

Four office chairs in a rowFor businessesAmazon Business is Amazon’s purchasing store for companies, with business accounts and quantity ordering.Register with Amazon Business

The undisclosed payload classes cut both ways for a reader of the deal. They protect Novartis's program plans from competitors, and they also mean nobody outside the two companies can yet say which cancers, or how many programs, the license actually covers. The $2 billion ceiling presumably scales with that hidden number. What is public is the structure: exclusive worldwide rights, a defined upfront, and milestones that pay OBI as Novartis's private plans turn into clinical facts.

The exclusivity is scoped, which matters for what OBI keeps. Novartis's rights cover the platform as applied to its selected payload classes. OBI, a clinical-stage oncology company founded in 2002 and headquartered in Taiwan with operations in the United States and Australia, retains its own drug programs and whatever platform uses fall outside the licensed classes. It's listed in Taipei under the ticker 4174.TWO.

For Novartis, the deal is one more purchase in oncology's most contested technology race. ADCs have produced some of the strongest-selling new cancer drugs of the decade, and every large drugmaker is either building conjugation capability in-house or renting it from a platform company. Renting it from OBI costs $30 million now and a defined share of any success later.

The test of the deal isn't the signing. It's whether a Novartis program built on GlycOBI chemistry reaches a clinic, then a filing, then a market. Each of those steps is a milestone payment to OBI and a public marker that the platform works inside someone else's pipeline. Until the first one lands, the $2 billion is arithmetic, not revenue.

Sources

The conversation

A little more perspective.

Reading is free. Verified members can comment and reply for $2 a month.

The conversation.

Loading comments…

Keep your curiosity going.

Some links here are affiliate links. If you buy through one, we might make a commission — it never changes what you pay. As an Amazon Associate I earn from qualifying purchases.